Drug Profile
PEPIDH1M
Alternative Names: Cancer vaccine - Annias Immunotherapeutics; Cytomegalovirus vaccine - Annias Immunotherapeutics; Cytomegalovirus-specific peptide vaccine - Annias Immunotherapeutics; Dendritic cell vaccine - Annias Immunotherapeutics; PEP CMVLatest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Duke University
- Developer Annias Immunotherapeutics; Duke University
- Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glioblastoma
- Phase I Glioma; Medulloblastoma
Most Recent Events
- 15 Nov 2023 The University of New South Wales plans a phase I trial in Glioblastoma (Newly diagnosed, Combination therapy) in November 2023 (NCT06132438)
- 08 Nov 2022 Servier plans a phase I ViCToRy trial for Glioma (Combination therapy, Recurrent) in USA (Intradermal) (NCT05609994)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Glioblastoma(In adolescents, In children, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intradermal, Injection)